Updates to the Handbook

Removal of 13vPCV and 23vPCV and addition of 21vPCV.

Removal of 13vPCV and 23vPCV and addition of 21vPCV.

Editorial and factual updates to information about the Australian Immunisation Register.

Editorial and factual updates to information about the Australian Immunisation Register.

Updated to reflect removal of 23vPPV.

Updated to reflect the new pneumococcal adult schedule.

Wording adding to reflect that adults with a risk condition aged 50-59 years can consider Arexvy vaccine and to clarify RSV monoclonal antibodies are recommended in each season if children aged <24 months remain at risk.  

Coadministration wording updated to align with changes in RSV chapter.

Additional clarifying wording regarding the spacing of LAIV relative to other live vaccines.

Updated to reflect the new pneumococcal adult schedule.

Coadministration wording updated to align with changes in RSV chapter.

Updates to the adult pneumococcal schedule with key changes including:

• 21vPCV replacing 13vPCV as the NIP-funded vaccine for adults aged over 18 years 
• Lowering of the recommended age for Aboriginal and Torres Strait Islander adults from 50 years to 25 years and older
• Lowering of the recommended age for all other adults without risk conditions from 70 years to 65 years and older
• Doses of 23vPPV are no longer required for any adults
• All adults regardless of previous pneumococcal vaccine history are recommended a dose of 21vPCV at least 12 months after their previous dose. 
• NIP-funded risk groups have expanded to now include chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema as well as chronic liver disease

A new table of guidance following vaccine errors has been added.

13vPCV and 23vPPV have been removed from all chapters in the AIH.

Other changes include the updated definition for harmful use of alcohol and updates to the epidemiology, adverse events and vaccine information sections. 

Updated to reflect addition of 21vPCV and removal of 13vPCV and 23vPPV including the addition of ‘histidine’ as a new component to the table.

Additional wording to clarify the spacing of LAIV relative to other live vaccines.

RSV added to the section on GBS.

Wording added to clarify that anaphylaxis ampules should be stored in original packaging. 
 

Updated to reflect the new pneumococcal adult schedule.

Wording adding to reflect that adults with a risk condition aged 50-59 years can consider Arexvy vaccine and to clarify RSV monoclonal antibodies are recommended in each season if children aged <24 months remain at risk.

Updated to reflect the new pneumococcal adult schedule.

Wording adding to reflect that adults with a risk condition aged 50-59 years can consider Arexvy vaccine and to clarify RSV monoclonal antibodies are recommended in each season if children aged <24 months remain at risk.

Minor updates to reflect the new adult pneumococcal vaccine schedule including lowering the recommended age from 50 years to 25 years and older.

Minor editorial updates to pneumococcal catch-up tables.

Updated to reflect 21vPCV as the NIP funded vaccine for adults and removal of 13vPCV and 23vPPV.

Updated to reflect availability of MenQuadfi MenACWY vaccine in the age group 6 weeks to less than 12 months, and addition of relevant dosing, safety and effectiveness data for this age group. Updated information on differences in recommended dosing schedules, between ATAGI and the product information, for different age groups.

Updated to reflect NIP-funding for RSV vaccine Arexvy for older adults aged ≥75 years and Aboriginal and Torres Strait Islander adults aged ≥60 years.

Updated to clarify timing of RSV-specific monoclonal antibodies in infants and co-administration in older adults.

Editorial changes to simplify the timing of RSV vaccination during pregnancy.

Season 3 efficacy and effectiveness data added for RSV vaccine Arexvy. 

Addition of intranasal route of administration and intranasal administration technique.

Updated advice on LAIV for people living or working in close contact with severely immunocompromised people.

Updated to include LAIV and to indicate it as a contraindication as necessary for specific immunocompromised groups.